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African American men have the highest incidence of prostate cancer in the world. Despite this statistic, linkage studies designed to
localise prostate cancer susceptibility alleles have included primarily men of Caucasian descent. In this report, we performed a linkage
analysis using 33 African American prostate cancer families from two independent research groups. In total, 126 individuals (including
89 men with prostate cancer) were genotyped using markers that map to five prostate cancer susceptibility loci, namely HPC1 at
1q24–25, PCAP at 1q42.2–43, CAPB at 1p36, HPC20 on chromosome 20, and HPCX at Xq27–28. Multipoint mode-of-inheritance-
free linkage analyses were performed using the GENEHUNTER software. Some evidence of prostate cancer was detected to HPC1
using all families with a maximum NPL Z score of 1.12 near marker D1S413 (P¼0.13). Increased evidence of linkage was observed in
the 24 families with prostate cancer diagnosis prior to age 65 years and in the 20 families with male-to-male transmission. Some
evidence of prostate cancer linkage was also detected at markers mapping to PCAP, HPC20, and HPCX. Continued collection and
analysis of African American prostate cancer families will lead to an improved understanding of inherited susceptibility in this high-risk
group.
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Prostate cancer has a higher incidence and mortality among
African American men compared to men of all other racial and
ethnic groups living in the US (Jemal et al, 2002). The explanation
for this observation is uncertain and may be due to a combination
of dietary, environmental and genetic factors. Family history has
been shown to be a strong risk factor for prostate cancer (see
review in Bratt, 2002), and this has led many research teams to
collect large prostate cancer families with the goal of identifying
prostate cancer susceptibility genes using linkage analysis. Review
of most published data, however, describes linkage evidence
primarily for Caucasian multiplex prostate cancer families
identified in North America and/or Europe.
Several population-based studies performed in the US and
Canada have demonstrated that the relative risk of prostate cancer
attributed to a family history of prostate cancer is similar between
individuals of African and Caucasian descent (Hayes et al, 1995;
Monroe et al, 1995; Whittemore et al, 1995). For example,
Whittemore et al (1995) reported data from a population-based
case–control study of prostate cancer among individuals of
African-, Caucasian-, and Asian descent from Los Angeles, San
Francisco, Hawaii, Vancouver, and Toronto. In their study, the
odds ratio associated with a family history of prostate cancer was
3.2 for individuals of African American descent (95% confidence
interval 2.0–5.0) and 1.9 for individuals of Caucasian descent (95%
confidence interval 1.2–1.9). Given the importance of prostate
cancer in African American families and the fact that the family
history is a significant risk factor for disease in this racial group,
we set out to study a set of multiplex prostate cancer families for
linkage to five previously reported prostate cancer susceptibility
loci: namely HPC1 at 1q24–25 (MIM 601518) (Smith et al, 1996),
PCAP at 1q42.2–43 (MIM 602759) (Berthon et al, 1998), CAPB at
1p36 (MIM 603688) (Gibbs et al, 1999), HPC20 on chromosome 20
(Berry et al, 2000b), and HPCX at Xq27–28 (MIM 300147) (Xu et al,
1998).
MATERIAL AND METHODS
Patient selection
A total of 33 African American families, including 19 families from
the University of Michigan Prostate Cancer Genetics Project
(PCGP) and 14 families from the Johns Hopkins University (JHU)
Family Collection, were analysed in this report. Each family has a
minimum of two genotyped affected men with prostate cancer in a
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sfirst- and/or second-degree relationship. For the 19 PCGP families,
all cases of prostate cancer were confirmed through review of
medical records or by independent report of two family members,
and all protocols were reviewed and approved by the University of
Michigan Institutional Review Board. Subsets of these families
have been included in prior linkage reports from our research
team (Cooney et al, 1997; Lange et al, 1999; Bock et al, 2001). A
total of 14 families were identified at the Brady Urology Institute at
JHU primarily through physician referral. The affection status and
age at diagnosis were confirmed either through medical records or
from two other independent sources. All participants gave full
informed consent and protocols were approved by the Johns
Hopkins University Institutional Review Board. Subsets of these
families have been included in prior linkage reports (Smith et al,
1996;Xu et al, 1998, 2001).
Laboratory methods
Genotyping was performed by either PCR using radiolabelled PCR
primers and acrylamide gel electrophoresis (Cooney et al, 1997) or
using fluorescently labelled makers with PCR products run on ABI
DNA sequencers (Smith et al, 1996). A common DNA CEPH
control (1347-02) was used to standardise allele sizes across
experiments. Marker selection and map position for loci on
chromosomes 1 and X are provided in Table 1. The panel of HPC20
markers used in the current study was nearly identical to those
reported in Berry et al (Berry et al, 2000b) and are shown in
Figure 1. Marker positions were determined by the Mammalian
Genotyping Service (MGS) website (http://research.marshfieldcli-
nic.org/genetics/Map_Markers/maps/IndexMapFrames.html).
Statistical analyses
Multipoint mode-of-inheritance-free linkage analyses were per-
formed using the statistical software package GENEHUNTER
versions 1.3. (for chromosome X) and 2.0b (for chromosomes 1
and 20) (Kruglyak et al, 1996). The marker allele frequencies were
estimated from the data using all genotyped individuals. Results
are reported in terms of standardised Z scores and their associated
P-values. In addition to analyses of the complete set of pedigrees,
stratified analyses were also performed on the subsets of pedigrees
using previously defined cutoff values for average age-of-diagnosis
of genotyped affected individuals, number of confirmed affected
individuals, and classification of male-to-male disease transmis-
sion.
RESULTS
A total of 126 individuals (including 89 confirmed prostate cancer
cases) were genotyped and included in the analyses. The clinical
characteristics of the families are described in Table 2. Seven of 33
families had very early-onset prostate cancer with an average age
of prostate cancer diagnosis within the family (based on ages of
men available for genotyping) of o55 years. Note that 20 out of 33
or 61% of families had evidence of disease transmission from
father to son that would be inconsistent with prostate cancer risk
being transmitted from the X chromosome.
Three regions of chromosome 1 were assessed for prostate
cancer linkage using a panel of polymorphic markers within each
region corresponding to the CAPB, HPC1, and PCAP putative
susceptibility genes. Some evidence in support of prostate cancer
linkage was observed in the HPC1 candidate region with a
maximum multipoint NPL Z score of 1.12 (P¼0.13) near marker
D1S413 (Table 3). The evidence for linkage was greater in the 24
families with an average age of prostate cancer diagnosis o65
years (Z¼1.68 near marker D1S413; P¼0.05) and the 20 families
with male-to-male transmission (Z¼1.73 near marker D1S413;
P¼0.04). The highest NPL Z score for the PCAP locus was
observed in the subset of 24 families with an average age of
prostate cancer diagnosis o65 years (maximum multipoint NPL Z
score of 1.48 near D1S2785, P¼0.07). The multipoint NPL Z scores
for markers corresponding to the CAPB locus were largely
negative.
A panel of chromosome 20 markers spanning nearly the entire
chromosome was used to assess the degree of linkage to HPC20
given the less exact location for this prostate cancer susceptibility
locus (Figure 1). Genotype data was available for 27 of the 33
families. The maximum multipoint NPL Z score for the entire set
of African American prostate cancer families was 1.17 near marker
D20S893 (P¼0.12) (Table 4). However, as with HPC1, increased
evidence of prostate cancer linkage was observed in the families
Table 1 Map position of markers used in prostate cancer linkage analysis for the four candidate regions on chromosomes 1 and X
CAPB Map position (cM) HPC1 Map position (cM) PCAP Map position (cM) HPCX Map position (cM)
D1S489 29.9 D1S452 188.9 D1S2678 256.3 DXS1205 87.6
D1S1597 29.9 D1S212 193.8 D1S2670 263.0 DXS1200 96.4
D1S402 31.0 D1S466 198.3 D1S2785 266.3 DXS1193 97.9
D1S407 33.8 D1S158 200.6 D1S321 267.5 DXS1113 98.1
D1S3669 37.1 D1S422 205.4 D1S304 267.5 DXS1108 104.3
D1S552 45.3 D1S413 212.4 D1S2842 273.5
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Figure 1 Linkage analysis using markers that span chromosome 20.
Markers used for this analysis are illustrated across the top of the figure, and
their map position is depicted across the bottom. For all 27 families as well
as each stratification,  log 10 of the P-value is plotted on the y-axis. Only
the stratifications of X5 affecteds, age at diagnosis o65 years, and male-
to-male transmission are shown.
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swith male-to-male transmission (Z¼1.64; P¼0.05) and with
average age of prostate cancer diagnosis less than age 65 years
(Z¼1.60; P¼0.05) near the same marker. Increased evidence of
linkage was also detected in the families with fewer than five
affected family members near marker D20S120 (Z¼1.46, P¼0.07).
The overall evidence of prostate cancer linkage to HPCX was
weakly positive with a maximum NPL Z score of 1.20 near marker
DXS1205 (P¼0.12) in 30 families. Note that two additional
families were removed from this analysis because all affected
individuals in these pedigrees could not share the same X
chromosome (e.g. paternal uncle and nephew pairs). None of the
stratifications provided increased evidence in support of HPCX
compared to the entire set of families.
DISCUSSION
This is the first report of prostate cancer linkage to putative
prostate cancer susceptibility loci using only families who are of
African American descent. Previous studies, including several
from our own research groups, have addressed potential prostate
cancer susceptibility loci in African American families through
stratification of large family data sets according to race. In this
report, we have combined two sets of African American pedigrees
from the University of Michigan PCGP and the JHU Family
Collection. While a subset of these pedigrees have been studied
previously, reanalysing the data in a combined analysis facilitates
stronger conclusions regarding evidence for linkage to the
described candidate regions in African Americans. The number
of pedigrees has been expanded since the original reports, and we
have attempted to use common markers for each locus.
Furthermore, the increased number of pedigrees enables subset
analyses incorporating only African American pedigrees. Subset-
ting pedigrees based on numbers of confirmed affected men, age at
diagnosis, and evidence of male-to-male transmission has been
invaluable in helping to localise candidate regions for prostate
cancer susceptibility genes. Small individual collections of African
American pedigrees have, until now, made the approach of
stratified analyses infeasible. The increased number of pedigrees
also enables better estimates of allele frequencies in the African
American population to be used in these analyses. This is relevant
since allele frequencies may vary according to race, and mis-
specification of allele frequencies may lead to spurious linkage
results. Finally, trying to piece together results from nonpara-
metric linkage analysis across different studies to assess the total
evidence for linkage is problematic. NPL Z scores are nonadditive,
and thus the evidence for linkage cannot be simply summed up
over all studies. While cumulative Z scores may be determined if
the number of pedigrees in each study is known, calculating the
degree of statistical significance (P-value) is far more difficult.
Taken together, there is a definite benefit to examining sets of
Table 2 Characteristics of African American prostate cancer families
No. of
families
Ave. no. of
confirmed affected
men/family
Ave. no. of
confirmed affected
men genotyped/family
Ave. age at
diagnosis of
cases/family
a
No. Families with
ave. age at diagnosis
65years
a
No. families with
male-to-male
transmission
University of Michigan PCGP 19 4.472.4 2.570.7 60.876.6 13 12
JHU family collection 14 5.473.5 3.171.5 59.576.8 11 8
aBased on those men available for genotyping.
Table 3 Summary of mode-of-inheritance-free linkage analyses using
markers that map to the three candidate loci on chromosome 1
Chromosome 1
Families
No. of
families Max NPL P-value
Nearest
marker
Region 1: CAPB
All 32  0.20 0.58 D1S552
¼4 5 affected 13  0.28 0.59 D1S552
o 5 affected 19  0.03 0.51 D1S552
¼4 65 years 8  0.01 0.52 D1S552
o 65 years 24  0.23 0.59 D1S552
Male-to-male 20  0.23 0.58 D1S552
Non male-to-male 12  0.04 0.51 D1S552
Region 2: HPC1
All 32 1.12 0.13 D1S413
¼4 5 affected 13 0.75 0.22 D1S413
o 5 affected 19 0.91 0.18 D1S158
¼4 65 years 8  0.03 0.52 D1S552/D1S452
o 65 years 24 1.68 0.05 D1S413
Male-to-male 20 1.73 0.04 D1S413
Non male-to-male 12  0.02 0.50 D1S552/D1S452
Region 3: PCAP
All 32 0.59 0.27 D1S2785
¼4 5 affected 13 0.37 0.34 D1S413/D1S2678
o 5 affected 19 0.88 0.18 D1S2785
¼4 65 years 8  0.67 0.73 D1S413/D1S2678
o 65 years 24 1.48 0.07 D1S2785
Male-to-male 20 0.88 0.18 D1S413/D1S2678
Non male-to-male 12  0.07 0.52 D1S321
Data from the marker with the most positive NPL Z score are provided. Rows that
are in bold text indicate NPL Z scores that are associated with statistically significant
P-values (Po0.05). One PCGP family was not genotyped for chromosome 1
markers.
Table 4 Summary of mode-of-inheritance-free linkage analyses using
markers that map to the HPC20 and HPCX candidate regions
No. of
families
Max
NPL P-value
Nearest
marker
Chromosome 20 families
All 27 1.17 0.12 D20S893
¼4 5 affected 11 1.02 0.15 D20S171
o 5 affected 16 1.46 0.07 D20S120
¼4 65 years 7 0.58 0.28 D20S195
o 65 years 20 1.60 0.05 D20S893
Male-to-Male 17 1.64 0.05 D20S893
Non male-to-male 10 0.33 0.36 D20S186
Chromosome X families
All 30 1.20 0.12 DXS1205
¼4 5 affected 12 0.77 0.21 DXS1200
o 5 affected 18 1.09 0.15 DXS1205
¼4 65 years 8 0.83 0.17 DXS1205
o 65 years 22 0.77 0.19 DXS1200
Male-to-male 18 0.84 0.22 DXS1205
Non male-to-male 12 0.86 0.20 DXS1205
Data from the marker with the most positive NPL Z score is provided. Rows that are
in bold text indicate NPL Z scores that are associated with statistically significant P-
values (Po 0.05). Note that six PCGP families were not genotyped for chromosome
20 markers and one PCGP family was not genotyped for chromosome X markers.
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spedigrees together as demonstrated by the analyses presented in
this report.
HPC1 at 1q24–25 has been the most widely studied prostate
cancer susceptibility locus. Although there have been both positive
and negative linkage reports, a meta-analysis using 772 hereditary
prostate cancer families from throughout the world revealed some
evidence for prostate cancer linkage with a peak NPL Z score of
1.14 at D1S212 (Xu, 2000). In this meta-analysis, the 491 families
with evidence of male-to-male disease transmission revealed
increased evidence for linkage with a peak NPL score of 2.30 at
D1S452. Review of earlier HPC1 linkage reports suggests that
African American prostate cancer families may have evidence of
disease linkage to 1q24–25 markers. In the Smith et al (1996)
study, the two African American families studied had a combined
LOD score of 1.4. This was followed up in a report from the
University of Michigan PCGP describing disproportionate evi-
dence for 1q24–25 linkage in six African American families from
the total sample of 59 families (Cooney et al, 1997). Our current
combined analysis is consistent with these earlier reports with
evidence for linkage to HPC1 in 32 families (for which genotype
data was available) studied together, as well as increased evidence
for linkage in families with early-onset disease and in families with
male-to-male transmission. Previous work from Gronberg et al
(1997) has emphasised that young age at diagnosis may be a
feature of HPC1-related prostate cancers. Recently, RNASEL has
been proposed to be a candidate for HPC1 (Carpten et al, 2002),
and a single African American prostate cancer family has been
shown to have a mutation in the initiating methionine occurring in
four of six brothers with prostate cancer. Sequencing of 16 African
American probands from a set of University of Michigan PCGP
families failed to identify this M1I or any other RNASEL mutations
(Chen et al, 2002), Further studies should be performed to
specifically test the role of RNASEL mutations in African American
prostate cancer families.
The two other prostate cancer susceptibility loci on chromo-
some 1 have not been specifically studied in African American
prostate cancer families, although the 14 JHU families were
included in a previously published analysis of all three chromo-
some 1 loci (Xu et al, 2001). The CAPB locus at 1p36 was described
by Gibbs et al (1999) in families with an excess of prostate cancer
as well as one or more cases of brain cancer in a first- and/or
second-degree relative. Review of the pedigrees from the 33
African American families described in this report reveals no cases
of primary brain cancer in first- and/or second-degree relatives.
Most of the linkage evidence in support of the PCAP locus at
1q42–43 is derived from families from France and England
(Berthon et al, 1998; Cancel-Tassin et al, 2001); many of the
published prostate cancer linkage studies in other populations
have not provided significant support for this putative locus (for
example, Berry et al, 2000a; Xu et al, 2001). In our study of 32
African American families in which genotype data was available,
we did not see significant evidence for linkage. However, the 24
families with average age of prostate cancer diagnosis less than age
65 years revealed some evidence for linkage with an NPL Z score of
1.48 near marker D1S2785 (P¼0.07). This is the same strata that
contributed significantly to the observation of prostate cancer
linkage in families from Southern and Western Europe (Cancel-
Tassin et al, 2001). Given the likelihood of locus heterogeneity for
prostate cancer, stratification by clinical phenotype (including
other cancers segregating in families and young age at diagnosis)
may help to elucidate the prostate cancer susceptibility genes
relevant to specific types of prostate cancer.
The HPCX locus was first described by Xu et al (1998) using a
set of 360 prostate cancer families. This locus is 50cM distal to the
androgen receptor locus, which maps to Xq11–q12. A previous
report from the University of Michigan PCGP provided some
additional support of the existence for the HPCX locus with
positive NPL Z scores across the candidate region. However, 11
African American families demonstrated no evidence of HPCX
linkage with negative NPL Z scores across the entire candidate
region (Lange et al, 1999). Addition of 19 more families in this
report has resulted in positive, although not statistically signifi-
cant, NPL Z scores using these same markers. Unfortunately, some
of the families described here exhibit only male-to-male transmis-
sion of disease. Thus, the stratifications result in small sets of
families that limit the conclusions that can be drawn from this
analysis.
Regarding the HPC20 locus, 14 African American prostate
cancer families from the PCGP have previously been shown to
provide evidence for prostate cancer linkage to this locus with a Zlr
of 1.99 between markers D20S893 and D20S120 (P¼0.023) (Bock
et al, 2001), whereas the 14 JHU families revealed negative NPL Z
scores using a similar set of markers. Despite these conflicting
results, the combined analysis of the 27 African American families
reported herein reveals suggestive evidence of linkage to HPC20
with a peak multipoint NPL Z score of 1.04 near D20S893
(P¼0.15). The subsets of African American families providing the
greatest evidence for linkage to HPC20 contains families with
evidence of male-to-male transmission (Z¼1.64, P¼0.05) and the
families with average of prostate cancer diagnosis o65 years
(Z¼1.60, P¼0.05). This contrasts with the initial report describ-
ing HPC20 in which the subset with the strongest evidence of
linkage to chromosome 20 markers was the 19 white families with
o5 affected family members, average age of prostate cancer
diagnosis 466 years and no evidence of male-to-male transmis-
sion (Berry et al, 2000b).
It should be noted that two African American JHU families
included in this report were also included in the original study by
Smith et al. (Smith et al, 1996), which suggested the importance of
HPC1 and HPCX in prostate cancer susceptibility. Removing these
two families from this current analysis resulted in slightly reduced
statistical significance estimates within these regions. For example,
the statistical significance of the evidence for linkage at marker
D1S413 in families with male-to-male transmission changed very
modestly (from P¼0.04 to P¼0.07). Given the limited number of
currently available African American pedigrees, we have chosen to
include these two families in the analyses of HPC1 and HPCX
described in this report.
In conclusion, this combined analysis of 33 African American
prostate cancer families provides continued support for the HPC1
and HPC20 loci as potentially important contributors to prostate
cancer susceptibility in this population. Analysis of these
additional African American prostate cancer families now provides
some evidence that HPCX may contribute to prostate cancer
susceptibility in this racial subgroup. Additionally, some new
evidence for the PCAP locus was identified particularly among
families with early-onset prostate cancer. Clearly, given the still
relatively small sample size of the current study and the resulting
modest power to detect linkage when present, no firm conclusions
should be drawn regarding the other candidate regions in regards
to susceptibility in the African American population. Continued
support for collection of DNA samples from African American
prostate cancer families and genome-wide analyses should help
illuminate the predisposing genes in this high-risk population.
However, given the relative difficulty in ascertaining African
American pedigrees, it is imperative that additional cooperative
studies such as this be undertaken to increase our ability to localise
and assess the role of prostate cancer susceptibility genes in this
population.
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